<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20150205020965N7</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-12-23</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>The effect of bitter almond gum supplement on type 2 diabetes</public_title>
      <acronym></acronym>
      <scientific_title>The effect of bitter almond gum supplement on the metabolic, inflammatory, and mental health indicators in women with type 2 diabetes</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-11-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>44</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/51883</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants in the study will be divided into two groups using balanced block randomization: 1) bitter almond gum consumer 2) placebo consumer. First, the quadruple Blocks and arrangement of blocks with their numbering will be determined. Then after the selection of specific blocks using a random number table and based on the number of blocks, entering the first four participants will be done. Then again, determination of the next block will be done using the random number table and this will continue until we reach the specified sample size, Blinding description: Bitter almond gum and maltodextrin (Both have the same taste, color, and smell) were delivered to patients monthly in similar cellophanes and unrecognizable without mentioning the type of supplement on the packages. In order to separate the two types of powders, in the factory, using a digital device, the code and date of production and expiration will be printed on the packages. In order for the researcher to be unaware of the patient's treatment, distribution of supplements, and placebo by another person Codes and type of supplement not known will be done. Until the study results are released, the patient, researcher, and data analyzer will not know the assigned codes.</study_design>
      <phase>3</phase>
      <hc_freetext>Type 2 diabetes.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Bitter almond gum. This group will dissolve and consume two sachets (2* 5 gr) of Bitter almond gum ( Payar Tejarat Zomorodin Company, Iran) twice a day, in the morning and in the evening, in lukewarm water for 2 months. Intervention 2: Control group: maltodextrin. This group will dissolve and consume two sachets ( 2*5 gr) of maltodextrin (Qinhuangdao Lihua Starch co, china) twice a day, in the morning and in the evening, in lukewarm water for 2 months.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Participant data will be presented in the article without identifiable details

When:
2020-2021

To whom:
Tabriz University of Medical Sciences

Conditions:
The application must be submitted to Tabriz University of Medical Sciences. It will available if Tabriz University of Medical Sciences is allowed.

Where to obtain:
Tabriz University of Medical Sciences

How to obtain:
The application must be submitted to Tabriz University of Medical Sciences. It will available if Tabriz University of Medical Sciences is allowed.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Parvin Dehghan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Golgasht Street, Tabriz, Iran</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614711</zip>
        <telephone>+98 33340634</telephone>
        <email>dehghan.nut@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Parvin Dehghan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Golgasht Street, Tabriz, Iran</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614711</zip>
        <telephone>+98 33340634</telephone>
        <email>dehghan.nut@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Having type 2 diabetes for more than six months according to International Diabetes Federation (fasting blood sugar level more than 126 mg/dl)
Age: 30-50 y
Using anti-diabetic drugs and maintaining them in the period of the study
Having a normal diet
Body Mass Index (BMI) more than 25 kg/m2 in the last 3 months</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>50 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Having a history of gastrointestinal
Having history cardiovascular
Having a history of renal
Having a history of thyroid
Having a history of liver; or pancreatic diseases
Pregnancy and lactating
Smokers
Consuming prebiotic and probiotics’ products</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E 11</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Type 2 diabetes mellitus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Bitter almond gum. This group will dissolve and consume two sachets (2* 5 gr) of Bitter almond gum ( Payar Tejarat Zomorodin Company, Iran) twice a day, in the morning and in the evening, in lukewarm water for 2 months.</i_keyword>
      <i_keyword>Control group: maltodextrin. This group will dissolve and consume two sachets ( 2*5 gr) of maltodextrin (Qinhuangdao Lihua Starch co, china) twice a day, in the morning and in the evening, in lukewarm water for 2 months.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Hemoglobin A1C (HbA1c). Timepoint: At baseline and two months after baseline. Method of measurement: Autoanalyzer.</prim_outcome>
      <prim_outcome>Lipid profile (TG, TC, HDL-c). Timepoint: At baseline and two months after baseline. Method of measurement: Autoanalyzer.</prim_outcome>
      <prim_outcome>Tryptophan. Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
      <prim_outcome>Kynurenine. Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
      <prim_outcome>Fasting glucose. Timepoint: At baseline and two months after baseline. Method of measurement: Colorimetric Assay Kit.</prim_outcome>
      <prim_outcome>Cortisol. Timepoint: At baseline and two months after baseline. Method of measurement: Eliza Kit.</prim_outcome>
      <prim_outcome>Glucagon-like peptide1. Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
      <prim_outcome>Fasting insulin. Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
      <prim_outcome>Carboxymethyl lysine. Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
      <prim_outcome>S-RAGE (soluble receptor for AGE). Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
      <prim_outcome>Nitric oxide. Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
      <prim_outcome>Interleukin 6. Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
      <prim_outcome>Highly sensitive C-reactive protein(hs-CRP ). Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
      <prim_outcome>Tumor Necrosis Factor (TNF). Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
      <prim_outcome>Interleukin 10 (IL10 ). Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
      <prim_outcome>Total antioxidant capacity. Timepoint: At baseline and two months after baseline. Method of measurement: Total Antioxidant Capacity (TAC) Assay Kit.</prim_outcome>
      <prim_outcome>Malondialdehyde. Timepoint: At baseline and two months after baseline. Method of measurement: Colorimetric Assay Kit.</prim_outcome>
      <prim_outcome>8-iso-prostaglandin F2α (8-iso-PGF2α). Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
      <prim_outcome>Leptin. Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
      <prim_outcome>Adiponectin. Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
      <prim_outcome>Ghrelin. Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
      <prim_outcome>PPAR-α expression. Timepoint: At baseline and two months after baseline. Method of measurement: Polymerase chain reaction (PCR).</prim_outcome>
      <prim_outcome>Lipopolysaccharide. Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
      <prim_outcome>Interleukin 17. Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
      <prim_outcome>CD 8  lymphocyte. Timepoint: At baseline and two months after baseline. Method of measurement: Fucitometry.</prim_outcome>
      <prim_outcome>Interleukin 1. Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
      <prim_outcome>CD 4  lymphocyte. Timepoint: At baseline and two months after baseline. Method of measurement: Fucitometry.</prim_outcome>
      <prim_outcome>Brain-derived Neurotrophic Factor. Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
      <prim_outcome>Vascular cell adhesion molecule cell (VCAM). Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
      <prim_outcome>Plasminogen activator inhibitor (PAI)-1. Timepoint: At baseline and two months after baseline. Method of measurement: Eliza kit.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Body Mass Index (BMI). Timepoint: At baseline and two months after baseline. Method of measurement: Scale-Meter.</sec_outcome>
      <sec_outcome>Daily macronutrient intake (Energy, carbohydrate, protein, fat). Timepoint: At baseline and two months after baseline. Method of measurement: Questionnaire (24-hour Dietary Recall).</sec_outcome>
      <sec_outcome>Waist circumference (WHR). Timepoint: At baseline and two months after baseline. Method of measurement: Calculation.</sec_outcome>
      <sec_outcome>Blood pressure. Timepoint: At baseline and two months after baseline. Method of measurement: Mercuric barometr.</sec_outcome>
      <sec_outcome>Assessment of the body composition. Timepoint: At baseline and two months after baseline. Method of measurement: Bioelectrical impedance analysis.</sec_outcome>
      <sec_outcome>Mental health. Timepoint: At baseline and two months after baseline. Method of measurement: Questionnaire (Depression Anxiety Stress Questionnaire, General Health Questionnaire  ).</sec_outcome>
      <sec_outcome>Appetite status. Timepoint: At baseline and two months after baseline. Method of measurement: Visual Analogue Scale Questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-10-17</approval_date>
        <contact_name>Ethics committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Tabriz University Of Medical Sciences, Nutrition Faculty, Attar Neyshabori Street, Golghash street. Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
